3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
28
Lymphoma, Mantle-Cell
14
Lymphoma, Non-Hodgkin
8
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma
5
Leukemia, B-Cell
4
Multiple Myeloma
3
Lymphoma, B-Cell
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Pancreatic Neoplasms
2
Lymphoma, Follicular
2
Lymphatic Diseases
2
Leukemia, Prolymphocytic
2
Leukemia
2
Squamous Cell Carcinoma of Head and Neck
1
Part1: Advanced B-cell Malignancies
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Hairy Cell
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Heart Failure
1
Glioblastoma
1
DLBCL
1
Interventions
Brentuximab Vedotin
20
Rituximab
10
pirtobrutinib
7
dacetuzumab
7
Doxorubicin
6
ruxolitinib
5
Vincristine
5
Prednisone
5
Lenalidomide
5
Cyclophosphamide
5
ponatinib
4
Imatinib Mesylate
4
Dexamethasone
4
Bendamustine Hydrochloride
4
Azacitidine
4
nilotinib
3
lintuzumab
3
Bortezomib
3
vosaroxin
2
venetoclax
2
spartalizumab
2
pomalidomide
2
ibrutinib
2
Rifampin
2
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
2
KW-2478
2
Ifosfamide
2
Gemcitabine
2
Etoposide
2
Dacarbazine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hematologic Diseases
×
acalabrutinib
×
Clear all
NCT04662255
2026-05-15
BRUIN-MCL-321
Eli Lilly and Company
Phase 3
Active not recruiting
500 enrolled